27.01.2021 | Insilico Biotechnology AG | News

Insilico announces the release of the Insilico Selector for accurate selection of high-performing cell clones using micro-scale data

Insilico Biotechnology AG announces the release of its new software product, the Insilico Selector. The revolutionary product allows for accurate prediction of clone performance at manufacturing scale based on data retrieved at micro-scale. As part of the Insilico AI Platform, the Insilico Selector allows for a significant reduction of process development timelines for biologics and biosimilars.


In recent years, time to market for new biologics is becoming more and more important to the biopharmaceutical industry. Faster time to market would always be translated to huge revenue gains for any biopharmaceutical company. Hence, there is an urgent need for tools that would enable the industry to accelerate clone selection without the risk of identifying false positive or false negative clones.

Traditionally, during the screening process, a specific clone of CHO cells is chosen according to productivity, cell growth, and stability. However, in many instances, the chosen clone would behave differently at manufacturing scale where the process conditions are significantly different. In a conventional clone selection procedure, therefore, there is a significant risk that false positive clones are selected and best performing clones are rejected. This would potentially lead to longer process development time. By contrast, Insilco’s new digital solution accurately predicts the performance of a specific clone at manufacturing scale based on a set of micro-scale data obtained during the very early stages of clone screening. The Insilico Selector thus makes sure that the optimal clones are identified.

Klaus Mauch, CEO of Insilico says: “The Insilico Selector is a Digital Twin-based tool that would greatly benefit the cell line development process. As part of our AI platform, this solution significantly reduces the timelines and resources required for process development”.

About Insilico
Insilico Biotechnology AG develops and delivers predictive Digital Twins to advance biopharmaceutical process development and manufacturing. Insilico Digital Twins of cell culture processes lead to superior productivity, product quality and process robustness. Ground breaking predictive power is achieved by exploiting process data using artificial intelligence and biochemical networks. As a result, Insilico’s unique approach substantially reduces experimental effort, costs of goods and time to market. Leading biopharmaceutical companies worldwide use Insilico Digital Twins for cell line development, media design and process control. Founded in 2001, Insilico Biotechnology is a privately held company based in Stuttgart, Germany.

Caroline Shafik
Public Relations Manager
Insilico Biotechnology AG